Background: Hot flashes affect as many as 75% of menopausal women. Estrogen reliably reduces the severity of hot flashes and remain the single most effective treatment. Today, however, more and more women are seeking alternatives. Instead of hormonal therapy, women are turning to vitamins, and other over-the-counter products for relief from hot flashes. This study was undertaken to assess the effect of vitamin E on hot flashes. Method: A placebo double blind-controlled trial was conducted. After 1 week baseline period, the enrolled patients (n = 51) received placebo (identical in appearance to vitamin E softgel) daily for 4 weeks, followed by 1 week wash out and 400 IU vitamin E (softgel cap) daily for the next 4 weeks. Diary was used to measure hot flashes before and at the end of the study. Result: There were statistical significant differences in hot flashes severity score (2.37 ± 0.74, 1.80 ± 0.87) and their daily frequency (5.00 ± 3.34, 3.19 ± 2.74) after the treatments between the placebo and vitamin E therapies (p < 0.0001). Conclusion: Based on our trial, vitamin E is recommended for the treatment of hot flashes.

A LT H 1 7 ( 2 0 1 4 ) A 7 1 9 -A 8 1 3were adapted respectively to screen independent risk factors of SMM, and a logistic model was set to predict the SMM by STATA 12.0. The areas under receiver operator characteristic (ROC) curve and agreement rate were used to evaluate the prediction model. Results: Three kinds of unexpected surgeries, transfusion, hysterectomy, ICU care, Multiple Organ Dysfunction Syndrome (MODS) were chosen as the outcomes of SMM by literature review and expert consensus. The rate of SMM was 2.30% in 33993 deliveries. All specified and substantially significant risk factors were divided in four aspects. Social characteristics included the hometown location of pregnant women. Pre-delivery characteristics were gestational weeks, multiparity, abnormal pregnancy history, PPH history and smoking. The coexisted diseases and complications of pregnancy were gestational hypertension, preeclampsia and eclampsia, other gestational hypertension diseases, placenta previa, placenta increta, hematological disease, cardiac disease and gynecological diseases. The delivery characteristics contained styles of onset labor, midwifery, episiotomy, macrosomia, fetal death, premature rupture of membrane, uterotonic treatment. The areas under ROC curve and agreement rate were 0.87 and 98.05% respectively. ConClusions: SMM can reflect the severe degree of maternal outcomes indirectly, but also illustrate potential maternal health in a country or area by providing information to influence the delivery of health services and health policy. Our model specified dozens of risk factors and had considerably higher value of ROC area and agreement rate. We will perform the prospective research to predict and prevent the SMM in future. PIH3THe effIcacy of oxImes In acuTe organoPHosPHorus PoIsonIng; an uPdaTed sysTemaTIc revIew and meTa-analysIs obJeCtiVes: To set a model to predict the Severe Maternal Morbidity (SMM) and specify the risk factors based on a registered study in Sichuan province, China. Methods: Overall 33993 deliveries of 8 hospitals in Sichuan province of China were consecutively collected between January 1, 2009, and December 31, 2010 in our database. The forward and backward stepwise regression methods